2526-64-9Relevant articles and documents
Studies on the structure behavior of triphenyldichlorophosphorane in different solvents
Yin, Qiang,Ye, Yong,Tang, Guo,Zhao, Yu-Fen
, p. 192 - 195 (2006)
Triphenyldichlorophosporane, which was prepared according to Appel reaction, was an efficient reagent for alkyl halide synthesis by virtue of having two replaceable groups on "pentavalent" phosphorus. The reaction of triphenylphosphine with hexachloroethane was investigated in different solvents and 31P NMR traced the processes of these reactions. As results, it was found that there was similar high coordinated phosphorus species formed in aromatic solvents and in ring ether type solvents, which had large 1JP-C (about 140 Hz) according to 13C NMR experiments. It is indicated that, for some solvent such as benzene or dioxane, solvent molecules might be locked in the high coordinated phosphorus compounds, which in turn would affect the triphenyl groups situated at the equatorial position.
An X-ray crystallographic study of the reagent Ph3PCl2; not charge-transfer, R3P-Cl-Cl, trigonal bipyramidal or [R3PCI]Cl but an unusual dinuclear ionic species, [Ph3PCl+...Cl-... +ClPPh3]Cl containing long Cl-Cl contacts
Godfrey, Stephen M.,McAuliffe, Charles A.,Pritchard, Robin G.,Sheffield, Joanne M.
, p. 2521 - 2522 (1996)
An X-ray crystallographic study of the reagent Ph3PCl2 reveals it to be [Ph3PCl+...Cl-... +ClPPh3]Cl and not trigonal bipyramidal, molecular charge-transfer Ph3P-Cl-Cl or the simple ionic species [Ph3PCl]Cl; this contrasts with the conclusions from all previous spectroscopic data recorded on compounds of stoichiometry R3PCl2 by earlier workers, and represents the first compound of this formula to be crystallographically characterised.
Synthesis of cationic gold(III) complexes using iodine(III)
Albayer, Mohammad,Dutton, Jason L.
, p. 1307 - 1321 (2019)
We report the synthesis and characterization of cationic Au(III) complexes supported by nitrogen-based ligands. The syntheses are achieved by reacting Au(I) complexes [Au(N-Me-imidazole)2]+ and [Au(pyridine)(NHC)]+ with iodine(III) reagents PhI(OTf)(OAc) and [PhI(pyridine)2]2+ yielding a series of cationic gold(III) complexes. In contrast, reactions of phosphine ligated gold(I) complexes with iodine(III) reagents results in the oxidation of the phosphine ligand.
Structural dependence of the reagent Ph3PCl2 on the nature of the solvent, both in the solid state and in solution; X-ray crystal structure of trigonal bipyramidal Ph3PCl2, the first structurally characterised five-coordinate R3PCl2 compound
Godfrey, Stephen M.,McAuliffe, Charles A.,Pritchard, Robin G.,Sheffield, Joanne M.
, p. 921 - 922 (1998)
The very delicate structural balance of Ph3PCl2 when prepared in diethyl ether solution is illustrated by its X-ray crystallographic study; unlike the ionic species, [Ph3PCl+...Cl-... +ClPPh3]Cl, which prevails in dichloromethane solution, the non-solvated molecular species Ph3PCl2 is formed in diethyl ether which is the first example of a trigonal bipyramidal R3PCl2 compound to be structurally characterised, and this may have an effect on the chlorinating ability of the reagent.
A practical one-pot transformation of triphenylphosphine oxide to triphenylphosphine by reduction of in situ generated triphenylphosphine dichloride
Yano, Tomotake,Hoshino, Masakatsu,Kuroboshi, Manabu,Tanaka, Hideo
, p. 801 - 803 (2010)
One-pot transformation of triphenylphosphine oxide to triphenylphosphine was achieved by the reaction of triphenylphosphine oxide with oxalyl chloride, which led to the formation of triphenylphosphine dichloride, and subsequent reduction of triphenylphosphine dichloride with a combination of aluminum-catalytic metal salt.
Chlorination of Phosphane Selenides
Upmann, Daniel,Jones, Peter G.
, p. 2776 - 2780 (2014)
Chlorination of the phosphane selenide iPrtBu2PSe with PhICl2 leads to the compound iPrtBu2PSe2Cl2, which contains a P-Se-SeCl2 moiety and is formally a phosphane selenide complex of selenium dichloride. Two polymorphs of the product were identified by X-ray structure analysis. The analogous reaction with tBu3PSe gave an oil, presumably tBu3PSe2Cl2, from which small quantities of tBu3PSe3Cl2 were obtained and characterized by X-ray structure analysis.
2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
-
Page/Page column 241; 242, (2021/06/26)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.
Pyrrolopyridinone derivative, preparation method thereof and application of pyrrolopyridinone derivative in medicine
-
Paragraph 0111; 0113-0116, (2019/03/10)
The invention relates to a pyrrolopyridinone derivative and a preparation method thereof and an application of the pyrrolopyridinone derivative in a medicine. Concretely, the invention relates to thepyrrolopyridinone derivative shown as a general formula (I) and the preparation method thereof and its medicinal salt, and the application of the compounds used as therapeutic agents, in particular asbromodomain protein inhibitors, wherein the definition of each substituent in the general formula (I) is the same as defined in the specification.
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
-
Page/Page column 540, (2019/02/13)
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
Long sought synthesis of quaternary phosphonium salts from phosphine oxides: Inverse reactivity approach
Vetter, Anna C.,Nikitin, Kirill,Gilheany, Declan G.
supporting information, p. 5843 - 5846 (2018/06/13)
Quaternary phosphonium salts (QPS), a key class of organophosphorus compounds, have previously only been available by routes involving nucleophilic phosphorus. We report the realisation of the opposite approach to QPS utilising phosphine oxides as the electrophilic partner and Grignard reagents as nucleophiles. The process is enabled through the crucial intermediacy of the derived halophosphonium salts. The route does not suffer from the slow kinetics and limited availability of many parent phosphines and a broad range of QPS were prepared in excellent yields.
